Kesler Norman & Wride LLC purchased a new position in Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report) during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm purchased 1,131 shares of the company’s stock, valued at approximately $379,000.
Other large investors have also added to or reduced their stakes in the company. Rise Advisors LLC bought a new stake in Medpace in the 1st quarter worth $27,000. Mather Group LLC. bought a new stake in Medpace in the 1st quarter worth $28,000. Fidelis Capital Partners LLC bought a new stake in Medpace in the 1st quarter worth $31,000. J.Safra Asset Management Corp grew its holdings in Medpace by 87.0% in the 1st quarter. J.Safra Asset Management Corp now owns 101 shares of the company’s stock worth $41,000 after acquiring an additional 47 shares during the last quarter. Finally, DT Investment Partners LLC bought a new stake in Medpace in the 2nd quarter worth $41,000. Institutional investors own 77.98% of the company’s stock.
Medpace Price Performance
Shares of NASDAQ MEDP opened at $338.16 on Wednesday. Medpace Holdings, Inc. has a 1 year low of $227.21 and a 1 year high of $459.77. The stock has a market cap of $10.48 billion, a P/E ratio of 34.47, a price-to-earnings-growth ratio of 1.88 and a beta of 1.35. The firm has a 50-day moving average of $362.27 and a 200 day moving average of $386.78.
Wall Street Analysts Forecast Growth
Several equities research analysts have recently commented on MEDP shares. StockNews.com cut shares of Medpace from a “buy” rating to a “hold” rating in a research report on Friday, September 27th. Jefferies Financial Group cut shares of Medpace from a “buy” rating to a “hold” rating and dropped their target price for the stock from $415.00 to $345.00 in a research report on Wednesday, September 25th. UBS Group cut shares of Medpace from a “buy” rating to a “neutral” rating and dropped their target price for the stock from $420.00 to $350.00 in a research report on Friday, September 27th. Guggenheim dropped their target price on shares of Medpace from $464.00 to $432.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Finally, TD Cowen dropped their target price on shares of Medpace from $452.00 to $434.00 and set a “buy” rating for the company in a research report on Wednesday, July 24th. Five analysts have rated the stock with a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $395.00.
Get Our Latest Analysis on Medpace
About Medpace
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
Featured Articles
- Five stocks we like better than Medpace
- Biggest Stock Losers – Today’s Biggest Percentage Decliners
- NVIDIA’s AI Dominance: Why Analysts Predict Major Upside Ahead
- What is a Secondary Public Offering? What Investors Need to Know
- These Stocks Are Using Buybacks to Unlock Big Gains for Investors
- How to Use the MarketBeat Excel Dividend Calculator
- This Is the Entry Into PepsiCo You’ve Been Waiting For
Want to see what other hedge funds are holding MEDP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medpace Holdings, Inc. (NASDAQ:MEDP – Free Report).
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.